This trial is testing whether adding Copanlisib to Durvalumab will help treat unresectable stage III NSCLC patients who have already undergone chemoradiation.
1 Primary · 3 Secondary · Reporting Duration: approximately 10 years
Experimental Treatment
18 Total Participants · 5 Treatment Groups
Primary Treatment: Copanlisib · No Placebo Group · Phase 1
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: